Navigation Links
Update on Preclinical Finding and Development Timeline for PCI-45292
Date:3/2/2011

SUNNYVALE, Calif., March 2, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that further advancement of PCI-45292, a Btk inhibitor with exceptionally potent anti-arthritis activity in mice and rats, has been suspended following results from the current set of preclinical toxicology studies.  The company hopes to have a new clinical development candidate identified within approximately 6 months.

PCI-45292 has been under preclinical development for approximately 1 year as a potential new agent for the treatment of immune mediated diseases. A recent evaluation of tissues from animals dosed with PCI-45292 has revealed an undesirable target-organ effect.  The effect, which was noted at all dose levels in a rat animal model, but absent in another animal model, precludes establishing a starting dose for human clinical trials.

The undesired effect observed with PCI-45292 has not been observed with our Btk Inhibitor PCI-32765 even at higher dose levels in preclinical safety studies and is not considered to be related to the inhibition of Btk.  Our broad clinical development for PCI-32765 in B-cell malignancies in particular in chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma continues as outlined in our last quarterly update.

We have readily identified the portion of the PCI-45292 molecule directly responsible for these target organ changes. We have now turned our attention to evaluating a related series of molecules with the focus on eliminating the target-organ effect.  Our commitment to advancing a safe and effective Btk inhibitor into the clinic for immune mediated diseases remains strong.

"While we are disappointed with the delay of the program we are pleased with the quality of the research that was able to identify this effect early in development, allowing us to make adjustments pre-clinically. We remain dedicated to developing important, new targeted therapies that are safe and effective and advance the standard of care for patients," said Bob Duggan, Chairman of the Board and Chief Executive Officer.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law. Contact:Ramses ErdtmannVice President of FinancePhone: 408-215-3325
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
2. Access Pharmaceuticals to Host Update Conference Call for Investors
3. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
4. China SHESAYS Updates on Progress of Commencing Operations at its New Flagship Hospital
5. ADVENTRX Pharmaceuticals Provides Update on ANX-514
6. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
7. Neuralstem Updates ALS Clinical Trial Progress
8. NeurogesX to Provide Qutenza® Launch Update
9. China SHESAYS Announces Preliminary Unaudited Results for FY 2010; Provides Business Outlook Update for Investors
10. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
11. PharmAthene Provides Update on Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... There are ... Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off ... 63 percent say grilling is their favorite way to cook a hot dog, far ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... in intellectual property (IP) to its specialty academic programs. , Answering to the ... college’s existing certificate programs in health law, and environmental and land use law. ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For Heroes ... in military battle for the country. The nonprofit Hope For Heroes partnered with ... that empower independence for disabled military veterans, as well as police, firemen, and EMS ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):